Nexalin Technology, Inc. (NXL)

Market Cap	18.09M
Revenue (ttm)	168,721
Net Income (ttm)	-7.61M
Shares Out	13.30M
EPS (ttm)	-0.83
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	427,813
Open	1.350
Previous Close	1.790
Day's Range	1.270 - 1.400
52-Week Range	0.530 - 4.490
Beta	4.65
Analysts	Strong Buy
Price Target	5.00 (+267.65%)
Earnings Date	May 13, 2025

About NXL

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer’s disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The compan...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Sep 16, 2022
• Employees: 6
• Stock Exchange: NASDAQ
• Ticker Symbol: NXL
• Website: https://www.nexalin.com

Financial Performance

In 2024, Nexalin Technology's revenue was $168,721, an increase of 52.35% compared to the previous year's $110,748. Losses were -$7.61 million, 63.6% more than in 2023.

Analyst Forecast

According to one analyst, the rating for NXL stock is "Strong Buy" and the 12-month stock price forecast is $5.0.

Price Target

$5.0

(267.65% upside)

Analyst Consensus: Strong Buy